Anxiety and Depression: Understanding the Risk for Preeclampsia
Rates of anxiety and depression have increased during the pandemic and are linked to preeclampsia risk, making screening for mental health conditions at prenatal visits essential.
General Psychiatry
Quviviq Now Available for Adults With Insomnia
Daridorexant is a dual orexin receptor antagonist designed to suppress wake drive by blocking the binding of wake-promoting neuropeptides orexin A and orexin B to its receptors.
Nonstimulant ADHD Treatment Option Approved for Adults
The approval was based on data from a phase 3 trial that assessed Qelbree in adults 18 to 65 years of age with ADHD.
Home Use of Ketamine
With ketamine gaining more attention to combat treatment-resistant depression (TRD), we look at the administration of ketamine through in-home measures.
A Perfect Storm: Rise in Eating Disorders Among Teens During COVID-19
Eating disorders among adolescents have doubled since the start of the pandemic and patients are presenting with more severe symptoms.
Igalmi Sublingual Film Approved for Agitation With Schizophrenia, Bipolar Disorder
The approval was based on data from the phase 3 SERENITY I and II studies that evaluated Igalmi for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II, respectively.
Low-FODMAP Diet and CBT for IBS: Efficacy Data and Individualizing Treatment
Authors describe efficacy data on the low-FODMAP-diet and CBT for IBS and factors to consider when personalizing treatment.
APA Releases DSM-5-TR Revisions
Developed by more than 200 experts, DSM-5-TR includes the fully revised text and references of the DSM-5, as well as updated diagnostic criteria and ICD-10-CM insurance codes.
New Tool May Help Reduce CVD Risk in Patients With Mental Illnesses
A clinical decisions support system provides personalized treatment recommendations on lowering cardiovascular risk factors in patients with schizophrenia, schizoaffective disorder, and bipolar disorder.
We Run Clinical Trials for Medications, Why Not for Apps?
The author comments on the current situation where behavioral modification smartphone apps do not undergo any oversight such as safety or efficacy studies, nor do they go through the Institutional Review Board to guide or evaluate ethics.
- Loading...
Loading...
Next post in Medicine
Loading... 
Loading...